These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12237534)

  • 1. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities.
    Nishida H; Miyazaki Y; Mukaihira T; Saitoh F; Fukui M; Harada K; Itoh M; Muraoka A; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Ohnishi S; Mochizuki H
    Chem Pharm Bull (Tokyo); 2002 Sep; 50(9):1187-94. PubMed ID: 12237534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor.
    Nishida H; Miyazaki Y; Kitamura Y; Ohashi M; Matsusue T; Okamoto A; Hosaka Y; Ohnishi S; Mochizuki H
    Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1237-44. PubMed ID: 11605647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors IV. A series of new derivatives containing a spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one skeleton.
    Nishida H; Mukaihira T; Saitoh F; Harada K; Fukui M; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Shiromizu I; Ohnishi S; Mochizuki H
    Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):406-12. PubMed ID: 15056953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Effect of ring opening of piperazinone moiety on inhibition.
    Nishida H; Miyazaki Y; Mukaihira T; Shimada H; Suzuki K; Saitoh F; Mizuno M; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Ohnishi S; Mochizuki H
    Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):459-62. PubMed ID: 15056966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
    Dudley DA; Bunker AM; Chi L; Cody WL; Holland DR; Ignasiak DP; Janiczek-Dolphin N; McClanahan TB; Mertz TE; Narasimhan LS; Rapundalo ST; Trautschold JA; Van Huis CA; Edmunds JJ
    J Med Chem; 2000 Nov; 43(22):4063-70. PubMed ID: 11063603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
    Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR
    J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.
    Hirayama F; Koshio H; Katayama N; Ishihara T; Kaizawa H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kurihara H; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2003 Feb; 11(3):367-81. PubMed ID: 12517432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.
    Buckman BO; Mohan R; Koovakkat S; Liang A; Trinh L; Morrissey MM
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2235-40. PubMed ID: 9873520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonbenzamidine tetrazole derivatives as factor Xa inhibitors.
    Quan ML; Ellis CD; He MY; Liauw AY; Woerner FJ; Alexander RS; Knabb RM; Lam PY; Luettgen JM; Wong PC; Wright MR; Wexler RR
    Bioorg Med Chem Lett; 2003 Feb; 13(3):369-73. PubMed ID: 12565931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitors.
    Su T; Yang H; Volkots D; Woolfrey J; Dam S; Wong P; Sinha U; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Feb; 13(4):729-32. PubMed ID: 12639568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors.
    Chou YL; Davey DD; Eagen KA; Griedel BD; Karanjawala R; Phillips GB; Sacchi KL; Shaw KJ; Wu SC; Lentz D; Liang AM; Trinh L; Morrissey MM; Kochanny MJ
    Bioorg Med Chem Lett; 2003 Feb; 13(3):507-11. PubMed ID: 12565961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.
    Arnaiz DO; Zhao Z; Liang A; Trinh L; Witlow M; Koovakkat SK; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):957-61. PubMed ID: 10853668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.
    Zhao Z; Arnaiz DO; Griedel B; Sakata S; Dallas JL; Whitlow M; Trinh L; Post J; Liang A; Morrissey MM; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):963-6. PubMed ID: 10853669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinnamyl derivatives: synthesis and factor Xa (FXa) inhibitory activities.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
    Chem Pharm Bull (Tokyo); 2008 Jun; 56(6):758-70. PubMed ID: 18520077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and molecular modelling of 1-amidinopiperidine thrombin inhibitors.
    Smolnikar I; Perdih A; Stegnar M; Prezelj A; Solmajer T; Urleb U; Obreza A
    Pharmazie; 2007 Apr; 62(4):243-54. PubMed ID: 17484277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors V. A series of new derivatives containing a spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one scaffold.
    Saitoh F; Mukaihira T; Nishida H; Satoh T; Okano A; Yumiya Y; Ohkouchi M; Johka R; Matsusue T; Shiromizu I; Hosaka Y; Matsumoto M; Ohnishi S
    Chem Pharm Bull (Tokyo); 2006 Nov; 54(11):1535-44. PubMed ID: 17077550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
    Stürzebecher J; Prasa D; Hauptmann J; Vieweg H; Wikström P
    J Med Chem; 1997 Sep; 40(19):3091-9. PubMed ID: 9301673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors.
    Huang W; Naughton MA; Yang H; Su T; Dam S; Wong PW; Arfsten A; Edwards S; Sinha U; Hollenbach S; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Feb; 13(4):723-8. PubMed ID: 12639567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
    Hirayama F; Koshio H; Katayama N; Kurihara H; Taniuchi Y; Sato K; Hisamichi N; Sakai-Moritani Y; Kawasaki T; Matsumoto Y; Yanagisawa I
    Bioorg Med Chem; 2002 May; 10(5):1509-23. PubMed ID: 11886813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
    Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.